$CGEM 8-K SEC Filings

Filed On	Filing
02 Oct 2026	8-K: Regulation FD Disclosure; Other Events New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
24 Sep 2026	8-K: Regulation FD Disclosure; Other Events Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November
14 Sep 2026	8-K: Regulation FD Disclosure; Other Events Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
13 Aug 2026	8-K: Regulation FD Disclosure; Other Events
06 Aug 2026	8-K: Results of Operations and Financial Condition
16 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
10 Jun 2026	8-K: Regulation FD Disclosure; Other Events
08 Jun 2026	8-K: Regulation FD Disclosure; Other Events
18 May 2026	8-K: Regulation FD Disclosure; Other Events
07 May 2026	8-K: Results of Operations and Financial Condition
10 Mar 2026	8-K: Results of Operations and Financial Condition
08 Jan 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
08 Dec 2025	8-K: Regulation FD Disclosure; Other Events
21 Nov 2025	8-K: Termination of a Material Definitive Agreement
06 Nov 2025	8-K: Results of Operations and Financial Condition; Other Events
03 Nov 2025	8-K: Regulation FD Disclosure; Other Events
04 Sep 2025	8-K: Regulation FD Disclosure; Other Events
07 Aug 2025	8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
12 Jun 2025	8-K: Submission of Matters to a Vote of Security Holders
04 Jun 2025	8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Comments